By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    medicare part d benefits
    Everything that You Need to Know About Medicare Part D
    August 15, 2022
    Best Ways to Boost Your Immune System this Winter
    Best Ways to Boost Your Immune System this Winter
    November 15, 2022
    back pain issues
    Ways to Treat Constant Back Pain
    August 21, 2023
    Latest News
    How Probate Planning Shapes the Future of Your Estate and Family Care
    July 17, 2025
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    More On Wellness Programs To Improve Health and Reduce Costs
    January 25, 2012
    Privatizing Social Security and Medicare: Who Can Defuse Political Dynamite?
    June 12, 2011
    Study: Risk of Death in Elderly Patients with Dementia Doubled with Some Antipsychotic Medications
    February 26, 2012
    Latest News
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
    How Health Choices and Legal Actions Intersect After an Injury
    July 17, 2025
    How communities and healthcare providers can address slip and fall injuries with legal awareness
    July 17, 2025
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
Technology

OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug

HerinaAyot
HerinaAyot
Share
3 Min Read
SHARE

OXiGENE (NASDAQ:OXGN) shares rose in pre-market trading on Monday as it announced on the weekend that follow-up results from a phase two study of Zybrestat showed that patients with non-small cell lung cancer had better response and survival rates.

The controlled, randomized trial, called Falcon, tested Zybrestat in combination with three other treatments, compared to the control arm of the study.

OXiGENE (NASDAQ:OXGN) shares rose in pre-market trading on Monday as it announced on the weekend that follow-up results from a phase two study of Zybrestat showed that patients with non-small cell lung cancer had better response and survival rates.

The controlled, randomized trial, called Falcon, tested Zybrestat in combination with three other treatments, compared to the control arm of the study.

More Read

understand the benefits of medical alert systems
Who Should Have a Medical Alert System?
Sensors Offer New Power to Improve Health
Yes, “Too Big” Can be a Problem in Device & Diagnostics Companies, Too
New Blood Test Could Help Doctors Figure Out Origins of Strokes
Small Bone Innovations Addresses Unmet Needs in Joint Replacement

An updated analysis, conducted roughly 11 months after enrollment of the last patient in June of last year, showed that the Zybrestat arm was well tolerated, with no significant cumulative toxicities. The partial response rate was 56% with Zybrestat, and 36% in the standard therapy arm.

In addition, a subgroup showed “meaningful improvements” in the average time to progression of the disease for patients with poor performance status, or sicker patients, OXiGENE said.

While the median time to progression for the overall patient population was similar in both arms of the study, those with poor performance status had a median time of 9.8 months in the Zybrestat arm, versus 3.8 months for the patients in the control group.

The company said that the suggestion that the Zybrestat combination could be especially beneficial in a sicker patient population should be explored in a larger trial.

“With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of Zybrestat,” said CEO Peter Langecker.

“In addition, this study provides data in non-small cell lung cancer suggesting that Zybrestat may benefit patients with more advanced stages of disease.

“We believe that designing a development plan based on targeting this subgroup of patients could represent a sensible and achievable clinical strategy.”

Zybrestat is a small-molecule drug that targets and collapses tumour cells by depriving them of oxygen, and it is being tested in studies of patients with non-small cell lung cancer, thyroid cancer, ovarian cancer and other clinical trials.

The updated data was presented at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.–Deborah Sterescu

Source

 

TAGGED:lung cancermedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
How IT and Marketing Teams Can Collaborate to Protect Patient Trust
Global Healthcare Policy & Law
July 17, 2025
paramedics in surgical gloves and masks
How Health Choices and Legal Actions Intersect After an Injury
Health care
July 16, 2025
a woman giving a key
How Probate Planning Shapes the Future of Your Estate and Family Care
Health
July 16, 2025
a woman with kinesio tapes on her back arm
How communities and healthcare providers can address slip and fall injuries with legal awareness
Health care
July 16, 2025

You Might also Like

6 Lessons from the World Cup for Medical Device Companies

July 24, 2014
can AI protect healthcare workers
Artificial IntelligenceCovid-19eHealthHealth careMobile HealthTechnology

How Can AI Protect Healthcare Workers From COVID-19 Transmission?

October 27, 2020
virtual hospital
Hospital AdministrationTechnology

MS Cloud for Healthcare: Enabling Virtual Hospital

August 12, 2024
Medical Device Marketing, Digital Marketing, PPC, SEO, SEM
BusinessMedical Devices

5 Online Statistics That Can Impact Medical Device Marketing

August 8, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?